Merck melanoma drug Keytruda OK'd; 1st US PD-1
This article was originally published in Scrip
Executive Summary
Merck won an earlier-than-expected approval from the FDA on 4 September to market Keytruda (pembrolizumab), previously known as lambrolizumab/MK-3475, as a treatment for unresectable or metastatic melanoma and disease progression in patients previously treated with Bristol-Myers Squibb's Yervoy (ipilimumab), and, if BRAF V600 mutation positive, a BRAF inhibitor.